Treatment with VU6047534, an experimental therapy that blocks the activity of a specific type of serotonin receptor, reduced strain on the heart in a mouse model of pulmonary arterial hypertension (PAH) in a new study. The study, “Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment…
A joint initiative between a Singapore-based medical technology company and Duke University is aiming to develop and commercialize artificial intelligence, or AI, tools for echocardiography — using ultrasounds to visualize the heart. Researchers from Us2.ai, the first new company created from an 11-country cardiovascular research platform, have teamed up…
Gradient Denervation Technologies has raised €14 million (around $14.9 million) in funding to support the clinical development and testing of an ultrasound-based catheter device for the treatment of pulmonary hypertension (PH). The minimally invasive catheter device is designed for use in the pulmonary arteries. It delivers therapeutic ultrasound…
An inhaled formulation of imatinib in development by Aerami Therapeutics to treat pulmonary arterial hypertension (PAH), was safe and well tolerated with few systemic side effects among healthy adults in a Phase 1 trial. AER-901, which is delivered via a smart, breath-activated nebulizer, also showed a distinct absorption…
Treatment with sotatercept in addition to standard pulmonary arterial hypertension (PAH) therapies significantly improved measures of heart health for adults with the disease, according to a new analysis of the STELLAR trial. Results from the Phase 3 trial had already shown the therapy enhanced walking abilities in the participants…
Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The risk profile was assessed using a risk score established to predict a response to treatment and survival in people with pulmonary arterial hypertension (PAH), the most common type…
A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early after an analysis showed the treatment is unlikely to help patients. The announcement was made in a press release from Janssen, the company that markets Opsumit. Opsumit…
The protein LTBP1 is active at high levels in pulmonary arterial hypertension (PAH) and may be a diagnostic marker and therapeutic target in the disease, a new study indicates. “Our study suggests that LTBP1 is involved in the development of PAH and serves as a potential diagnostic and therapeutic…
AI Therapeutics has begun dosing in a clinical trial testing inhaled LAM-001, a potential disease-modifying therapy for pulmonary arterial hypertension (PAH). The 24-week, open-label Phase 2 study (NCT05798923) is recruiting 15 adults at Brigham and Women’s Hospital in Boston, Massachusetts. All participants should have advanced PAH…
Psychological counseling and therapy are among the interventions that may help adults with pulmonary hypertension (PH) manage depression and anxiety, a review paper reports. Data in this area are limited, however, and the review highlighted a need for more research into how best to support the mental health…
Scientists have identified gene, protein, and signaling pathway alterations in the livers of people with portopulmonary hypertension (PoPH) — a form of pulmonary arterial hypertension (PAH) usually associated with liver disease — that could reflect underlying mechanisms of the rare disorder. Compared with liver disease patients without PoPH, those…
Engaging in inspiratory muscle training for eight weeks may help people with pulmonary hypertension (PH) strengthen their respiratory (breathing) muscles and gain exercise capacity, a study suggests. This is important because inspiratory (breathing in) muscle training may offer a non-invasive approach to improve the quality of life and overall…
Get regular updates to your inbox.